openPR Logo
Press release

Global Monoclonal Antibodies Pipeline Insight 2015

06-30-2017 08:28 AM CET | Health & Medicine

Press release from: PNS Pharma

Ever since the Nobel Prize was bestowed on the person who invented the technology which enabled the preparation of monoclonal antibodies in 1984, their use has considerably expanded far beyond the scientific realm. Paul Ehrlich framed a hypothesis that a “magic bullet” could be developed with an objective of targeting selective diseases. With the introduction and development of hybridoma technology by Kohler and Milstein, this hypothesis has become a reality. These monoclonal antibodies have come to be known as highly valuable therapeutic agents. This technology rendered mAbs to be highly potential of specific associations with their targeted antigens.Muromonab-CD3 (Orthoclone OKT3; Ortho Biotech) was the first of these antibodies which was approved in 1986, in the prevention of acute transplant rejection. This has been followed by an increasing number of other monoclonal antibodies, of which many were among the best-selling drugs across the globe.

Utility of mAbs in therapeutic treatment have been widely accepted among physicians and patients across the globe. This could be attributed to their high specificity due to which only diseased cells are eliminated while normal cells are spared. Their ability to bind target is high because they are made by using single antigen giving them high specificity. As a result, side effects are minimized as compared to other therapeutics available in global market. They are bit larger than other therapeutic molecules but they are highly customizable due to which they could be designed for particular disease. Clinical data has also shown that they have high safety and efficacy profiles due to which more patients are willing to include them in their regular therapeutic regime. They could be used to treat various ailments like cancer, auto-immune, anti-inflammatory and other disease indications. Out of these ailments, cancer mAb segment occupies major market shares and generates huge revenues across the globe. Pharmaceutical companies are trying to develop them for more ailments in other to generate diversify and strengthen their portfolio.

Download Report:

http://www.pnspharma.com/buy-report.php?reporttitle=Global-Monoclonal-Antibodies-Pipeline-Insight-2015

Different mAbs have different action mechanism due to which they can be used against multiple malignancies. Depending upon malignancy in question, mAb could be customized due to which their dominance in global cancer market could be observed. For instance, rituximab is used for lymphoma treatment; it binds to the cancerous cells and makes it more susceptible to attack by immune system. On the other hand, Ibritumomab for Non-Hodgkin Lymphoma (NHL) treatment consists of radioactive pay load to eliminate cancerous cells. Chemotherapeutics are one of the major contenders having largest market shares in cancer category but their severe side effects noticeable during treatment. To alleviate patients’ medical condition pharmaceutical companies have also launched the mAb version of chemotherapeutics. For instance, ado-trastuzumab emtansine has been launched in market for Her 2 positive breast cancer treatment.

With existing product pipelines on the verge of being exhausted, it is most likely that the future years would witness an increased level of investments from the pharma companies so as to fill up their R&D pipelines. Additionally, a significant amount of research is being currently conducted to improve the level of potency of monoclonal antibodies. Cancer is becoming a major area where the use of monoclonal antibodies is increasing substantially in the recent years. In the future also, this field is expected to have the maximum application of mAbs.

“Global Monoclonal Antibodies Pipeline Insight 2015” Report Highlight:

* Monoclonal Antibodies Classification
* Mechanism of Monoclonal Antibodies
* Global Monoclonal Antibodies Market Overview
* Global Monoclonal Antibodies Clinical Pipeline by Company, Indication & Phase
* Global Monoclonal Antibodies Clinical Pipeline: 1096 mAb
* Marketed Monoclonal Antibodies: 66 mAb
* Global Cancer Monoclonal Antibodies Clinical Pipeline: 602 mAb
*Marketed Cancer Monoclonal Antibodies: 34 mAb

For Report Sample Contact: rajesh@pnspharma.com or :Visit :
https://www.pnspharma.com

Recent Publication

* Global Peptide Therapeutics Market & Clinical Trials Insight
* Global Orphan Drug Clinical Pipeline Insight 2022

PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.

Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
8-9, Ansal Building
Dr. Mukherjee Nagar
Delhi, India

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Monoclonal Antibodies Pipeline Insight 2015 here

News-ID: 602994 • Views: 227

More Releases from PNS Pharma

Global Gene Therapy Market Opportunity By Clinical Trials Pipeline sales Kymriah …
"Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026" Report Highlight: o Global Gene Therapy Market Opportunity: > US$ 8 Billion o Global Gene Therapy Clinical Pipeline: > 1000 Therapies In Clinical Trials o Commercially Available Gene Therapies: 11 o USA Dominates Global Gene Therapy Pipeline: > 500 Therapies In Clinical Trials o Cancer Accounts For 50% of Global Gene Therapy Trials Download Report: https://www.pnspharma.com/buy-report.php?reporttitle=Global-Gene-Therapy-Market-Opportunity-%26-Clinical-Trials-Insight-2026 Over the years, gene therapy has been highly responsible for decreasing the mortality rate
Global Orphan Drug Market Clinical Trials Pipeline Report Market Study 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: o Global Orphan Drug Market Opportunity: US$ 300 Billion o US Dominates Global Orphan Drug Market: 50% Market Share o US Orphan Drug Opportunity To Surpass: US$ 150 Billion o Global Orphan Drug Clinical Insight: More Than 900 Drugs o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs o Oncology To Dominate Orphan Drug Development: 35% Share o FDA & EMA Regulations For Orphan Drugs o Orphan Drug Designation Criteria
Global Rare Disease Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: o Global Orphan Drug Market Opportunity: US$ 300 Billion o US Dominates Global Orphan Drug Market: 50% Market Share o US Orphan Drug Opportunity To Surpass: US$ 150 Billion o Global Orphan Drug Clinical Insight: More Than 900 Drugs o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs o Oncology To Dominate Orphan Drug Development: 35% Share o FDA & EMA Regulations For Orphan Drugs o Orphan Drug Designation Criteria
Global Orphan Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: o Global Orphan Drug Market Opportunity: US$ 300 Billion o US Dominates Global Orphan Drug Market: 50% Market Share o US Orphan Drug Opportunity To Surpass: US$ 150 Billion o Global Orphan Drug Clinical Insight: More Than 900 Drugs o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs o Oncology To Dominate Orphan Drug Development: 35% Share o FDA & EMA Regulations For Orphan Drugs o Orphan Drug Designation Criteria

All 5 Releases


More Releases for Monoclonal

Global Cancer Monoclonal Antibodies Market &Clinical Trial Insight 2024
" Global Cancer Monoclonal Antibodies Market &Clinical Trial Insight 2024" Report Highlights: * Significance for Monoclonal Antibodies for Cancer Treatment * Global Cancer Monoclonal Antibodies Market Overview * Global Cancer Monoclonal Antibodies Pipeline by Phase & Indication * Global Cancer Monoclonal Antibodies Pipeline: 697 mAb * Marketed Cancer Monoclonal Antibodies: 60 * Global Cancer Monoclonal Antibodies Market Opportunity: US$ 140 Billion The recent years have witnessed the emergence of monoclonal antibodies, which has the potential
Monoclonal Antibodies market In Depth overview by Experts 2018
The Monoclonal Antibodies market outlook of the global industry is provided based on the Monoclonal Antibodies growth drivers, constraints and threats, SWOT analysis, and Monoclonal Antibodies market share study. The drivers and constraints of Monoclonal Antibodies industry recognize the rise and fall of the Monoclonal Antibodies market. The study is served based on the Monoclonal Antibodies haggling power of buyers, haggling power of suppliers, the risk of new entrants, the
Monoclonal Antibody Custom Service Market Ravishing Growth with CAGR of 10.84% | …
Complete Study of Monoclonal Antibody Custom Service Market Research Report is added on MarketResearchFuture.com with Latest Advancement. Detail analysis on possible segments and sub segments of the market. Along with this regional analysis of the market which includes North America, Europe, Asia Pacific and Middle East and Africa. Avail Premium Sample Copy @ https://www.marketresearchfuture.com/sample_request/4515 Monoclonal Antibody Custom Service Market – Overview It is estimated that monoclonal antibody custom service market is expected to
Global Monoclonal Antibodies Pipeline Analysis
The market for monoclonal antibodies (mAB) has become the fastest growing segment of the pharmaceutical industry. In 2012, there were more than 30 monoclonal antibody therapies approved by the FDA which generated annual sales of more than US$ 40 Billion. As the therapeutic mABs already play a significant part in effective medical treatment, it is most likely that their importance would increase by manyfolds in the future. There has been a
Global Cancer Monoclonal Antibodies Pipeline Analysis
In the past few years monoclonal antibodies have emerged as a therapeutic modality for cancer. These monoclonal antibodies are designed to selectively target cancer cells and extract various responses, thus indirectly protecting the non cancerous cells. This characteristic of monoclonal antibodies coupled with increasing potential of the oncology market has made many pharmaceutical giants to invest a significant portion of their R&D on cancer monoclonal antibodies. In recent years the popularity
Global Cancer Monoclonal Antibodies Market & Pipeline Insight
The recent years have witnessed the emergence of monoclonal antibodies, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past decades, the researchers have increased their learning about the human body’s immune system, which has led to the achievement of significant number of regulatory milestones during this period. The use of mAbs for treating cancer has increased significantly. The rising market availability